PMID- 7989932
OWN - NLM
STAT- MEDLINE
DCOM- 19950112
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 12
IP  - 12
DP  - 1994 Dec
TI  - Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in 
      first complete remission: a comparative study. French Group of Therapy of Adult 
      Acute Lymphoblastic Leukemia.
PG  - 2580-7
AB  - PURPOSE: Optimal postremission therapy remains controversial in adult patients 
      with acute lymphoblastic leukemia (ALL). In a large multicentric trial (LALA87), 
      we compared allogeneic bone marrow transplantation (BMT) with other postremission 
      therapies (chemotherapy or autologous transplantation) using the result of the 
      human leukocyte antigen (HLA) typing as a random allocation. PATIENTS AND 
      METHODS: Patient eligibility requirements were as follows: (1) inclusion in 
      LALA87 trial, (2) complete response to induction or salvage therapy, (3) age 15 
      to 40 years, and (4) at least one potential sibling donor. Patients with an 
      HLA-identical sibling were assigned to the BMT group, while patients without a 
      sibling donor constituted the control group. Allogeneic transplantation was 
      scheduled for patients in the BMT group; in the control group, patients were 
      randomly allocated to receive chemotherapy or autologous transplantation. 
      RESULTS: Of 284 eligible points, 257 entered the study: 116 were allocated to the 
      BMT group and 141 to the control group. The 5-year survival rates were not 
      statistically significantly different between the two groups. When only patients 
      with high-risk ALL were considered (those with [1] Philadelphia chromosome [Ph1] 
      ALL, [2] null or undifferentiated ALL, or [3] c-ALL with either age greater than 
      35 years or WBC count > 30 x 10(9)/L or time to achieve complete remission > 4 
      weeks), overall survival (P = .03) and disease-free-survival (P = .01) were 
      better for the BMT group compared with the control group (5-year overall survival 
      rates, 44% v 20%; 5-year disease-free survival rates, 39% v 14%). CONCLUSION: 
      Allogeneic transplantation does not improve survival in patients with 
      standard-risk ALL and should be recommended only for patients with adverse 
      prognostic factors.
FAU - Sebban, C
AU  - Sebban C
AD  - Department of Hematology, Hopital Edouard Herriot, Lyon, France.
FAU - Lepage, E
AU  - Lepage E
FAU - Vernant, J P
AU  - Vernant JP
FAU - Gluckman, E
AU  - Gluckman E
FAU - Attal, M
AU  - Attal M
FAU - Reiffers, J
AU  - Reiffers J
FAU - Sutton, L
AU  - Sutton L
FAU - Racadot, E
AU  - Racadot E
FAU - Michallet, M
AU  - Michallet M
FAU - Maraninchi, D
AU  - Maraninchi D
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 5J49Q6B70F (Vincristine)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - COP protocol 2
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - *Bone Marrow Transplantation
MH  - Cyclophosphamide/administration & dosage
MH  - Female
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/*therapy
MH  - Prednisone/administration & dosage
MH  - Prognosis
MH  - Remission Induction
MH  - Survival Rate
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
MH  - Vincristine/administration & dosage
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1200/JCO.1994.12.12.2580 [doi]
PST - ppublish
SO  - J Clin Oncol. 1994 Dec;12(12):2580-7. doi: 10.1200/JCO.1994.12.12.2580.